Abstract:
The invention relates to compounds that are diazahomoadamantane derivatives, compositions comprising such compounds, and methods of using such compounds and compositions.
Abstract:
The invention relates to amine-substituted aza-adamantane derivatives, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. Radiolabelled compounds useful for evaluating the binding affinity to a7 nicotinic acetylcholine receptors also are described.
Abstract:
The invention relates to heterocyclic derivatives, compositions comprising such compounds, and methods of preventing or treating conditions and disorders using such compounds and compositions. The heterocyclic derivatives, more particularly can be substituted oxadiazole compounds and derivatives thereof.
Abstract:
This invention relates to novel quinuclidine derivatives represented by Formula (II) wherein represents an optional double bond; n is 1, 2 or 3; X represents a linker selected from -O-, -O-CH 2 -, -O-CH 2 -CH 2 -, -S-, -SO-, -SO 2 -, -CH 2 -, -S-CH 2 -CH 2 -,-CH 2 -, -C(=CH 2 )-, -NH-, -N(alkyl)-, -C(=O)-, -C(=S)-, oo, and ss; and Y represents O, S, SO 2 , or NR ’ wherein R ’ represents hydrogen or alkyl and their use as pharmaceuticals. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
Abstract:
The present application relates to calcium channel inhibitors containing compounds of formula (I) wherein L 1 , L 2 , R 1 , R 2 , and R 3 are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.
Abstract:
The invention relates to novel amide derivatives that are positive allosteric modulators of neuronal nicotinic receptors, compositions comprising the same, processes for preparing such compounds, and methods for using such compounds and compositions.
Abstract:
TThe invention relates to compounds that are acetamide and carboxamide derivatives of azaadamantane, compositions comprising such compounds, and methods of using such compounds and compositions.
Abstract:
Compounds of formula (I) wherein n is 0, 1, or 2; A is N or N+-O-; X is O, S, -NH-, and -N-alkyl-; Ar1 is a 6-membered aromatic ring; and Ar2 is a fused bicycloheterocycle. The compounds are useful in treating conditions or disorders prevented by or ameliorated by a7 nAChR ligands. Also disclosed are pharmaceutical compositions having compounds of formula (I) and methods for using such compounds and compositions.
Abstract:
Compounds of formula (I) wherein A and B are amine-substituted sidechains, Y 1 and Y 2 form various tricyclic cores, X a and X b are C, CH, or N, as defined herein, and R x is an optional substituent. Compounds and compositions of formula (I) are contemplated as well as methods for treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands that encompass compounds of formula (I) and other tricyclic derivatives. Methods of using amino-substituted tricyclic derivatives also are described herein.
Abstract:
The invention relates to a composition comprising a neuronal nicotinic receptor ligand and an α4β2 positive allosteric modulator, a method of using the same, and a related article of manufacture.